RedHill Biopharma Ltd.: Q3 results did not meet expectations mainly with GI drug sales; financially, capital raising of $20.6M (NIS 1.94 per share) positions Redhill with sufficient funds until 2018.

RedHill announces top-line results from Phase III study of RHB-104 in Crohn’s Disease; cash balance improved with $25M (gross) raised at a discount; Top-line results for TALICIA® (RHB-105) – H. pylori infection expected by the end of 2018; target price reduced to NIS 2.23